Brii Biosciences (“Brii Bio”) and Columbia University have entered into a memorandum of understanding through which Brii Bio will provide funding to support research to be conducted by investigators at the university and led by David Ho, M.D., founding scientific director of the Aaron Diamond AIDS Research Center and professor of medicine at the Vagelos College of Physicians and Surgeons.
Kuur Therapeutics announced the launch of its new business in partnership with Baylor College of Medicine and Baylor’s Center for Cell and Gene Therapy. Houston-based Kuur Therapeutics will advance the work of its predecessor, Cell Medica, to develop anti-cancer therapies using its innovative chimeric antigen receptor natural killer T cell (CAR-NKT) therapy platform.
Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology.
Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing.
Merck, known as MSD outside the United States and Canada, and the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, today announced the publication of research on the discovery of a novel class of candidate antimalarial agents that block multiple stages of the lifecycle of the parasite that causes the disease.
Japanese pharmaceutical firm Takeda has commenced the development of a plasma-derived therapy for COVID-19, a disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2).
Iktos, a French artificial intelligence (AI) start-up company, has joined forces with California-based research institute SRI International to accelerate discovery and development of therapies for the Wuhan coronavirus (COVID-19) and other viruses.
Akouos, Inc. (“Akouos”), a precision genetic medicine company developing potential gene therapies to restore, improve or preserve hearing, today announced it has raised $105 million in an oversubscribed Series B financing.
Gilead Sciences has signed an agreement to acquire clinical-stage immuno-oncology company Forty Seven for $4.9bn.
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, announced a new strategic direction to accelerate the advancement of certain of its clinical development programmes.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.